Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?
about
Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsThe quest to overcome resistance to EGFR-targeted therapies in cancer.Should peri-gastrectomy gastric acidity be our focus among gastric cancer patients?The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers.The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria.Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation.A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization.Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria.EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?pH-dependent drug-drug interactions for weak base drugs: potential implications for new drug development.Acquired resistance to TKIs in solid tumours: learning from lung cancer.Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial.BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs.Nanoparticulation improves bioavailability of Erlotinib.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.The pharmacogenomics of drug resistance to protein kinase inhibitors.Newer medical therapies for metastatic soft tissue sarcoma.Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options.Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.Drug-drug interactions in patients receiving tyrosine kinase inhibitors.Effect of acid suppressants on the efficacy of tyrosine kinase inhibitors in patients with epidermal growth factor receptor-mutated non-small-cell lung cancer.Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.Proton pump inhibitors increase the chemosensitivity of patients with advanced colorectal cancer.The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVCIntegrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent.Combining "Bottom-up" and "Top-down" Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC-0941) Pharmacokinetics.Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers.Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption.Drug interactions produced by proton pump inhibitors: not simply a pH effect.Understanding and targeting resistance mechanisms in NSCLC.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions.Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects.Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects.
P2860
Q28550276-DE72D715-DDAF-4A9B-B222-6AD9A7F28C25Q33725976-D81B5998-8D12-4854-8DD3-7C08C627DAEAQ33735357-3EBECE3E-77DD-4262-9D14-913606975684Q34079756-2A303FA1-68A8-43E3-A23E-D1D9E338C496Q35318395-7CCEA62A-FAD9-4B84-AA12-C76A527D6207Q36262855-2D7F4F35-88BC-4B1F-9B96-D4B23A6453A4Q37527859-0AA837BC-3CD3-4B00-8652-B7EAAE68FE19Q37624513-F45C474C-F25B-4545-AE5D-34FD593E257BQ37709182-DCE51BC5-8900-446C-97D5-527342DE2624Q38198997-30CFC15F-D7DA-4E44-A658-5D18C3340017Q38204680-46362F04-BF84-44F2-9336-9F6B25F5895BQ38224967-6A38D867-5913-4DFE-95CF-FB8523C01E93Q38351470-65CD1DA1-432E-43BD-96A8-57EC2EBC0448Q38386642-618E9678-4EF4-4C86-992C-29F6C852E349Q38640797-575B64F2-7252-46AE-AF9B-23D50152E158Q38701944-2F2B13E3-7079-42C5-B915-3B521B5C5C19Q38937228-C33F29C8-CDC6-464E-9AB3-1DB71D9D16A9Q38952751-65A640BC-F50C-4D90-BD17-3E9BADE54AF0Q39012067-789937AF-5A82-4390-AB03-A12AEE09CD26Q39013343-C59FA169-8A01-4AD5-904C-E30672AD394BQ39031326-F9CBB578-ABEF-48FA-B60B-309E16CA49DEQ39111080-22F6A2BB-233D-4093-94E0-865344E8B6B3Q40480137-43DBC351-E186-4676-ACA1-E6176EF1290FQ41634946-3E9EB473-B9C9-4C81-9091-C98EC99A0759Q41709117-A17A1A17-0AAB-4552-8EEB-5EE71CFDA223Q41948835-59E5CF14-67E8-4231-B9B6-225F8D26320CQ43451983-507419F8-4E73-4442-B1B3-B073BC649DC4Q43515674-47F26562-AE07-40BE-9234-236B331F6706Q45063196-3D13163B-A077-4F0C-950B-A948B7C8FB5BQ45977183-8098DB3D-AD50-4E3B-9F89-BA06E8B49858Q46307133-49C69B80-F774-4BEA-998E-91649BE47900Q46349067-DE519F2F-BDAC-44BE-8611-F19EC75796DBQ46879485-5A0FE0A7-966E-49F9-B2D5-D6B2208216A5Q46915997-E01371E5-B406-4A55-9AD0-4EA592312048Q47969048-0A85EC95-BAF8-4598-B17E-6A3563146F65Q48157676-81F677A1-DD97-40C2-8B60-39AB9BF2DBCBQ50711101-D4AC71CC-4BCA-4CB7-A888-DDFF352E4D9DQ51046580-D31CFF59-CFF5-4AF7-A0DE-AE3247028724Q55017122-46F859AA-0051-4807-A2EB-3AD4C5C7FC9CQ55060584-396DB69B-12CF-46D5-85BC-2B71BBD370E0
P2860
Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Drug absorption interactions b ...... lles heel of targeted therapy?
@en
type
label
Drug absorption interactions b ...... lles heel of targeted therapy?
@en
prefLabel
Drug absorption interactions b ...... lles heel of targeted therapy?
@en
P2093
P2860
P356
P1476
Drug absorption interactions b ...... lles heel of targeted therapy?
@en
P2093
A Frymoyer
G S Smelick
M J Dresser
S N Holden
P2860
P304
P356
10.1038/CLPT.2012.73
P407
P577
2012-06-27T00:00:00Z